The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
Pfizer reported that its ultra-long-acting, once-monthly GLP-1 injectable achieved up to 12.3% placebo-adjusted weight loss ...
Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.
Pfizer made one thing clear this week: It's officially back in the obesity race.
Considerable on MSN
Lilly’s Zepbound seen beating Pfizer injection
Eli Lilly’s Zepbound is still viewed as the leading weight-loss shot, according to a ...
By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...
PFE stock today: Pfizer's stock dipped despite strong fourth-quarter earnings. Investors reacted to the company's modest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results